GLP1R and Alzheimer disease: This data led to a Phase IIb clinical trial (NCT01843075) that demonstrated Liraglutide’s potential to improve cognitive function and MRI volume in patients with mild-to-moderate AD [227], leading to optimism about GLP1 analogs as a potential disease-modifying therapy for AD.